Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

16.79 +0.08 (+0.48%)
Streaming Delayed Price Updated: 3:41 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ascentage Pharma Group International - American Depository Shares

News headline image
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
News headline image
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
From ASCENTAGE PHARMA GROUP INTERNATIONAL
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.